The ASX healthcare sector edged higher this week as investors processed the final round of annual general meetings. The S&P/ASX 200 Health Care index (ASX:XHJ) climbed 0.85% over five days, outpacing the broader S&P/ASX 200 (ASX:XJO), which rose 0.73%.
Clarity Pharmaceuticals surges after FDA breakthrough
Clarity Pharmaceuticals (ASX:CU6) resumed trading on Thursday with a 23% jump following the U.S. Food and Drug Administration’s award of Breakthrough Therapy designation to its prostate-cancer imaging agent 64Cu-SAR-bisPSMA. This designation targets detection of recurrent prostate cancer, known as biochemical recurrence.
He stated that it adds further credibility to the clinical outcomes achieved to date because the regulator has reviewed and independently backed the Co-PSMA and COBRA data.
Wilkie cautioned that the designation does not eliminate risk surrounding upcoming Phase III results, expected in the first half of calendar year 2027. He added that it improves the regulatory pathway rather than the efficacy case, but it adds weight to the Co-PSMA signal heading into Phase III readout.
The consensus price target for CU6 shares stands at $7.20.
BlinkLab’s autism-gene study shows distinct sensory signatures
BlinkLab (ASX:BB1) disclosed positive findings from an exploratory study involving participants with SHANK2-related autism. Using its Dx1 smartphone-based assessment, researchers identified a sensory-processing signature that differed markedly from siblings and matched controls.
The study enrolled 20 individuals through the SHANK2 Foundation, including children with SHANK2-related autism and unaffected siblings. Using a 15-minute smartphone assessment, researchers compared results with 99 matched controls, measuring startle responses, sensory processing and behaviour using the same technology behind BlinkLab Dx1. The assessment identified a distinct sensory processing signature in participants with SHANK2 mutations. Prepulse inhibition, a measure of the brain’s ability to filter background stimuli, was reversed in the SHANK2 group at –26.5%, versus 27.8% in unaffected siblings and 27.2% in controls – a gap of roughly 54 percentage points.
Other metrics, including habituation to repeated sounds and postural stability, also displayed significant variation. The results remained statistically significant after adjusting for age and sex, while overall startle magnitude did not change.
Power highlighted that Dx1’s ability to detect underlying brain biology, not just observable behaviour, strengthens the investment case for the platform. He stated that this supports the broader investment case for BB1 Dx1 and highlights a potential future role in clinical trials and drug development.
Nanosonics gains additional FDA clearance
Nanosonics announced a second FDA 510(k) clearance for its Coris automated channel-cleaning system, expanding the device’s approved scope.
The clearance adds several high-volume colonoscopes and gastroscopes, addressing a key requirement for hospitals seeking fleet-wide solutions.
While a United States launch date remains pending, the company continues a controlled market release across the United Kingdom, Ireland and Australia.
Analysts anticipate that the upcoming fiscal-year commentary may provide a clearer launch timeline and early installation metrics.
Avita Medical upgrade and earnings outlook
AVH upgraded its FY26 revenue guidance to US$92-94 million from US$86-89m and reaffirmed fourth-quarter cash flow breakeven.
Revenue increased 53% year-on-year to US$26.1m, while operating expenses remained flat and net cash use fell to just US$600,000. Operating leverage has now shown up in the numbers, and cash flow breakeven looks to be a quarter early.
The company’s Recell wound-care line posted a notable increase quarter-on-quarter, and the Cohealyx burn-care segment reported strong year-on-year growth.
Ansell maintains guidance and strategic priorities
Ansell kept its earnings-per-share outlook for the fiscal year intact following its AGM, citing continued strength in the United States market.
Constant-currency sales rose in the first quarter, underpinned by sustained demand across North America.
The recent implementation of an enterprise-resource-planning system removed a near-term operational risk, though broader system upgrades are still planned.
The newly appointed chief executive outlined three primary priorities: commercial excellence, targeted investment in attractive markets, and simplification of operations.
Cost-out initiatives aim to generate US$50 million in recurring savings, with additional efficiency measures slated for the coming months.
EBR Systems safety update and commercial reset
EBR Systems issued updated safety guidance for diagnostic ultrasound examinations in patients implanted with its WiSE cardiac resynchronisation therapy system.
The advisory focuses on circumstances where external ultrasound could trigger inappropriate pacing, particularly within a month of implantation.
Since the September announcement, the firm identified seventeen events among 586 implanted patients, including a single fatality.
Incidence per examination remains low, and the company does not anticipate a material impact on commercial activities or financial position.
EBR reported an adjusted EBITDA loss for the third quarter that was narrower than analyst forecasts.
Management highlighted early momentum in the fourth quarter and is pursuing repeat procedures across a network of purchasing agreements and trained physicians.
The firm is recruiting a new chief commercial officer, while the chief executive assumes direct oversight of commercial operations.
